Comparatively, the largest EV biomarker study to date before the current study was in 200 patients with stable CAD reporting the prognostic value of CD31+/Annexin V+ EVs for MACE in a 6-year follow-up with an HR of 4.0.37 This evidence concerns the gene ANXA5 and coronary artery disorder.